Role of caspases and apoptosis-inducing factor (AIF) in cladribine-induced apoptosis of B cell chronic lymphocytic leukemia

Leukemia

Volumn 16, Issue 10, 2002, Pages 2106-2114

  Perez Galan P ^a   Marzo, I ^a   Giraldo, P ^b   Rubio Felix D ^b   Lasierra, P ^c   Larrad, L ^c   Anel, A ^a   Naval, J ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

2 chloro 2 deoxyadenosine; 9 D arabinofuranosyl 2 fluoradenine; Apoptosis inducing factor (AIF); B cell chronic lymphocytic leukaemia (B CLL); Caspases

Indexed keywords

APOPTOSIS INDUCING FACTOR; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CLADRIBINE; FLUDARABINE PHOSPHATE; PHOSPHATIDYLSERINE; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL DEATH; CELL NUCLEUS; CHROMATIN CONDENSATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MITOCHONDRION; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

EID: 0036799354     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402650     Document Type: Article

References (39)

1. Kipps TJ. Chronic lymphocytic leukemia. Curr Opin Hematol 2000; 7: 223-234.
2. Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737-743.
3. Stoetzer OJ, Pogrebniak A, Scholz M, Pelka-Fleischer R, Gullis E, Darsow M, Nssler V, Wilmanns W. Drug-induced apoptosis in chronic lymphocytic leukemia. Leukemia 1999; 13: 1873-1880.
4. Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell lymphocytic leukemia. Blood 1999; 94: 2836-2843.
5. Pettitt AR, Cawley JC. Caspases influence the mode but not the extent of cell death induced by purine analogues in chronic lymphocytic leukaemia. Br J Haematol 2000; 109: 800-804.
6. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA, Leoni LM. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000; 96: 3537-3543.
7. Marzo I, Perez-Galan P, Giraldo P, Rubio-Felix D, Anel A, Naval J. Cladribine induces apoptosis in human leukaemia cells by caspase- dependent and -independent pathways acting on mitochondria. Biochem J 2001; 359: 537-546.
8. Martinez-Lorenzo MJ, Alava MA, Gamen S, Kim KJ, Chuntharapai A, Pineiro A, Naval J, Anel A. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 1998; 28: 2714-2725.
9. m loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res 2000; 258: 223-235.
10. Gamen S, Anel A, Pineiro A, Naval J. Caspases are the main executioners of Fas-mediated apoptosis, irrespective of the ceramide signalling pathway. Cell Death Differ 1998; 5: 241-249.
11. Krajewski S, Zapata JM, Reed JC. Detection of multiple antigens on Western blots. Anal Biochem 1996; 236: 221-228.
12. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143-150.
13. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, Brothers CM, Mangion J, Jacotot E, Costantini P, Loeffler M, Larochette N, Goodlett DR, Aebersold R, Siderovski DP, Penninger JM, Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 1999; 397: 441-446.
14. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990-4997.
15. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang H-G, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379-3389.
16. Dumont C, Drrbach A, Bidère N, Rouleau M, Kroemer G, Bernard G, Hirsch F, Charpentier B, Susín SA, Senik A. Caspase-independent commitment phase to apoptosis in activated blood T lymphocytes: reversibility at low apoptotic insult. Blood 2000; 96: 1030-1038.
17. Reed JC. Molecular biology of chronic lymphocytic leukemia: implications for therapy. Semin Hematol 1998; 35: 3-13.
18. Panasci L, Paiement J-P, Christodoulopoulos G, Belenkov A, Malapetsa A, Aloyz R. Chlorambucil drug resistance in chronic lymphocytic leukemia: The emerging role of DNA repair. Clin Cancer Res 2001; 7: 454-461.
19. Bellosillo B, Colomer D, Pons G, Gil J. Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 1998; 100: 142-146.
20. Rabizadeh E, Bairey O, Aviram A, Ben-Dror I, Shaklai M, Zimra Y. Doxorubicin and a butyric acid derivative effectively reduce levels of BCL-2 protein in the cells of chronic lymphocytic leukemia patient. Eur J Haematol 2001; 66: 263-271.
21. Robak T, Blonski JZ, Kaasznicki M, Blasinska-Morawiec M, Krykowski E, Dmoszyniska A, Mrugala-Spiewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasinski I, Zdziarkska B, Kotlarek-Haus S, Potoczek S, Grieb P. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000; 96: 2723-2729.
22. Carrera CJ, Piro LD, Saven A, Beutler E, Terai C, Carson DA. 2-Chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. Adv Exp Med Biol 1991; 309A: 15-18.
23. Sun XM, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM. Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 1999; 274: 5053-5060.
24. Slee EA, Adrain C, Martin SJ. Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem 2001; 276: 7320-7326.
25. Zamzami N, Marchetti P, Castedo M, Zanin C, VayssiŁre JL, Petit PX, Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 1995; 181: 1661-1672.
26. Perkins C, Kim CN, Fang G, Bhalla KN. Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res 1998; 58: 4561-4566.
27. MacFarlane M, Cain K, Sun XM, Alnemri ES, Cohen GM. Processing/activation of at least four interleukin-1 beta converting enzyme-like proteases occurs during the execution phase of apoptosis in human monocytic tumor cells. J Cell Biol 1997; 137: 469-479.
28. McCarthy NJ, Whyte MK, Gilbert CS, Evan GI. Inhibition of Ced-3/ICE-related proteases does not prevent cell death induced by oncogenes, DNA damage, or the Bcl-2 homologue Bak. J Cell Biol 1997; 136: 215-227.
29. Huang P, Robertson LE, Wright S, Plunkett W. High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells. Clin Cancer Res 1995; 1: 1005-1013.
30. Leoni LM, Chao Q, Cottam HB, Genini D, Rosenbach M, Carrera CJ, Budihardjo I, Wang X, Carson DA. induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc Natl Acad Sci USA 1998; 95: 9567-9571.
31. Genini D, Budihardjo I, Plunkett W, Wang X, Carrera CJ, Cottam HB, Carson DA, Leoni LM. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J Biol Chem 2000; 275: 29-34.
32. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 1990; 265: 16617-16625.
33. Catapano CV, Chandler KB, Fernandes DJ. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate. Cancer Res 1991; 51: 1829-1835.
34. Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 2000; 14: 1405-1413.
35. Sfikakis PP, Dimopoulos MA, Souliotis VL, Charalambopoulos D, Mavrikakis M, Panayiotidis P. Effects of 2-chlorodeoxyadenosine and gold sodium thiomalate on human bcl-2 gene expression. Immunopharmacol Immunotoxicol 1998; 20: 63-77.
36. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SA. In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues: correlation with clinical course. Leukemia 1998; 12: 1230-1235.
37. Gottardi D, De Leo A, Alfarano A, Stacchini A, Circosta P, Gregoretti MG, Bergui L, Aragno M, Caligaris-Cappio F. Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations. Br J Haematol 1997; 99: 147-157.
38. Pepper C, Thomas A, Hoy T, Fegan C, Bentley P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br J Haematol 2001; 114: 70-77.
39. Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, Erdjument-Bromage H, Tempst P, Korsmeyer SJ. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem 1999; 274: 1156-1163.